MX2024005589A - Combinaciones de lurbinectedina y atezolizumab. - Google Patents

Combinaciones de lurbinectedina y atezolizumab.

Info

Publication number
MX2024005589A
MX2024005589A MX2024005589A MX2024005589A MX2024005589A MX 2024005589 A MX2024005589 A MX 2024005589A MX 2024005589 A MX2024005589 A MX 2024005589A MX 2024005589 A MX2024005589 A MX 2024005589A MX 2024005589 A MX2024005589 A MX 2024005589A
Authority
MX
Mexico
Prior art keywords
lurbinectedin
atezolizumab
combinations
treatment
lung cancer
Prior art date
Application number
MX2024005589A
Other languages
English (en)
Spanish (es)
Inventor
Muñoz Salvador Fudio
Rodriguez Luis Gonzaga Paz-Ares
Aix Santiago Ponce
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of MX2024005589A publication Critical patent/MX2024005589A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2024005589A 2021-11-08 2022-11-08 Combinaciones de lurbinectedina y atezolizumab. MX2024005589A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21383013 2021-11-08
PCT/EP2022/081155 WO2023079177A1 (en) 2021-11-08 2022-11-08 Lurbinectedin and atezolizumab combinations

Publications (1)

Publication Number Publication Date
MX2024005589A true MX2024005589A (es) 2024-05-23

Family

ID=78820304

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005589A MX2024005589A (es) 2021-11-08 2022-11-08 Combinaciones de lurbinectedina y atezolizumab.

Country Status (9)

Country Link
US (1) US20240415834A1 (https=)
EP (1) EP4430075A1 (https=)
JP (1) JP2024540417A (https=)
KR (1) KR20240099455A (https=)
AU (1) AU2022381992A1 (https=)
CA (1) CA3237009A1 (https=)
IL (1) IL312263A (https=)
MX (1) MX2024005589A (https=)
WO (1) WO2023079177A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025228595A1 (en) * 2024-04-30 2025-11-06 Pharma Mar, S.A. Use of compound ia in the treatment of cancers including combination therapy with atezolizumab.
WO2025228594A1 (en) * 2024-04-30 2025-11-06 Pharma Mar, S.A. Use of ecubectedin in the treatment of cancers including combination therapy with atezolizumab

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102232L (sv) 2001-06-25 2003-02-06 Anoto Ab Förfarande och anordning i ett digitalt kommunikationssystem
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
JP2023503318A (ja) * 2019-11-21 2023-01-27 ファルマ、マール、ソシエダード、アノニマ ルルビネクテジン製剤で小細胞肺がんを処置する方法

Also Published As

Publication number Publication date
KR20240099455A (ko) 2024-06-28
AU2022381992A1 (en) 2024-05-16
JP2024540417A (ja) 2024-10-31
WO2023079177A1 (en) 2023-05-11
EP4430075A1 (en) 2024-09-18
CA3237009A1 (en) 2023-05-11
US20240415834A1 (en) 2024-12-19
IL312263A (en) 2024-06-01

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
MY205856A (en) Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
MX2021013218A (es) Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2.
PH12021551047A1 (en) Anti-ptk7 immune cell cancer therapy
WO2019006418A3 (en) ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
AU2018372763A1 (en) Materials and methods for treatment of autosomal dominant Retinitis Pigmentosa
CA3055791A1 (en) Treatment methods
WO2019067666A8 (en) Therapeutic methods relating to hsp90 inhibitors
ZA201800931B (en) Selection of patients for combination therapy
MX2024005589A (es) Combinaciones de lurbinectedina y atezolizumab.
MX2022002699A (es) Lurbinectedina en el tratamiento del mesotelioma maligno.
MX2021003062A (es) Terapia combinada para tratar el cancer de sangre.
WO2020055643A3 (en) Compounds, compositions and methods for treating or preventing her-driven cancers
WO2019143883A3 (en) Compositions and methods for the treatment of cancer
WO2021081457A3 (en) Methods and agents for enhancing t cell therapies
IL307465A (en) Combined therapies for cancer treatment
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
PH12022551008A1 (en) Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
WO2021041716A3 (en) Therapeutic editing to treat cardiomyopathy
WO2019224385A3 (en) Combined bispecific antibody and immuno-oncology therapies
MX2023006087A (es) Formulaciones liofilizadas de tegavivint.
WO2020033019A3 (en) Novel mct4 inhibitors and uses thereof
PH12021550035A1 (en) Combination therapy